Bioactive lipids and herbal therapeutic regimens in the management of emerging SARS-CoV-2 variants: Further insights

Despite the development and implementation of vaccinations, the SARS-CoV-2 pandemic has persisted for more than two years due to emerging novel variants. The new Omicron lineages are being intensively monitored by WHO. Scientists from all over the world have reported the recombinant variants, but their existence remains a point of contention. Currently, XE and BA.2 are the most common variants. Deltracron (a recombinant of Delta and Omicron) has been discovered in several investigations, although some experts believe the sequences that confirm its emergence are the product of contamination. This study looked at emerging variants including XD, XE, and XF, as well as various omicron lineages (BA.1, BA.2, BA.3, BA.4, and BA.5). Bioactive lipids including arachidonic acid, docosahexaenoic acid, and eicosapentaenoic acid have been highlighted as possible COVID-19 therapeutics. On the other hand, herbal remedies are supposed to be the key player in minimizing the fatality rates in India. Coronil, a herbal formulation was found to be the evidence-based medicine against SARS-CoV-2. The activity of the Coronil is attributed to its diverse bioactive composition which includes cordifolioside A, rosmarinic acid, magnoflorine, withaferin A, ursolic acid, withanone, palmatine, betulinic acid, withanoside IV, and withanoside V. The interaction of bioactive lipids, Coronil and SARS-CoV-2 emerging variants might be beneficial in the management of pandemic until the herd immunity is achieved.